$ query --field mechanism
How PT-141 Works: Melanocortin Receptor Agonism
PT-141 acts on the brain's melanocortin receptors, not on blood flow — a central mechanism that sets it apart from every vascular erectile-dysfunction drug.
Start here
A melanocortin receptor agonist is a molecule that switches on a specific family of receptors — the melanocortin receptors — the way a key turns a lock. PT-141 (bremelanotide) is one of these. The receptors it cares about, called MC4R and MC3R, sit mostly inside the brain, in regions that govern sexual desire and arousal [1]. That is the headline: PT-141 works in the brain, not in the blood vessels. Older erectile-dysfunction pills (the PDE-5 inhibitor class) work on the plumbing — they relax vessel walls so blood flows more easily. PT-141 does something different. It nudges the neural circuits that create the feeling of desire in the first place [1]. The body makes a natural version of this signal, alpha-MSH; PT-141 is a lab-made copy designed to last longer. Below, each step of that mechanism is laid out and sourced — none of it is a treatment instruction.
The receptors PT-141 acts on
PT-141 is a synthetic analogue of alpha-MSH (alpha-melanocyte-stimulating hormone), the body's own melanocortin signal. It binds and activates melanocortin receptors — a family of five G-protein-coupled receptors (MC1R through MC5R) — with its main action at MC4R and a secondary action at MC3R [1]. MC4R and MC3R are the central-nervous-system members of that family, concentrated in the hypothalamus and limbic system. In animal studies, systemic PT-141 activated hypothalamic neurons, measured as a rise in the activity marker c-Fos, which is direct evidence the compound is reaching and switching on brain circuits rather than acting only at the periphery [1]. A review of melanocortin pharmacology places bremelanotide squarely within this MC3R/MC4R drug class for male and female sexual dysfunction [11].
Brain, not blood flow
The clearest way to understand the mechanism is by contrast. PDE-5 inhibitors are peripheral: they act on vascular smooth muscle to improve erectile blood flow. PT-141 is central: it acts on the neural circuitry of sexual motivation [1]. By stimulating MC4R in hypothalamic regions such as the medial preoptic area (an anterior-hypothalamus region important for sexual motivation), it is thought to engage dopamine-using pathways tied to desire and arousal. A randomized, placebo-controlled brain-imaging (fMRI) study of 31 premenopausal women with HSDD gave this mechanism direct human support: MC4R agonism significantly increased sexual desire for up to 24 hours and changed task-based brain processing — enhancing connectivity between the amygdala and insula and activity in cerebellar and supplementary-motor regions — in response to erotic stimuli [5].
What the mechanism does not explain
A central mechanism does not mean an unlimited one. A 2025 study in female Syrian hamsters found that MC3R/MC4R messenger RNA was concentrated in dopamine neurons of the ventral tegmental area, but that bremelanotide did not change melanocortin-receptor expression in the mesolimbic dopamine system and did not enhance sexual reward in a conditioned-place-preference test — suggesting it does not act on the brain's core reward circuit [6]. Two common misconceptions are worth correcting directly: PT-141 does not work through the HPG axis and does not directly raise testosterone, and it is not a PDE-5 inhibitor and does not act on vascular smooth muscle [1]. The receptor target also reaches beyond sex: MC4R sits in appetite circuits too, which is why high-frequency dosing in early metabolic studies affected caloric intake — a pharmacological fact, not an approved use [1]. The full menu of PT-141 benefits is sorted on its own page.